ERT Facilitates Global Growth with Appointment of Klaus Besier to Board of Directors

Industry Expert Brings Significant Record of Executive
Leadership in Sales, Marketing and Global Business Development to
Growing Company

PHILADELPHIA, PA 14 December 2010 ERT, a global
provider of technology and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
appointment of Klaus Besier to the Company’s Board of
Directors. This strategic appointment will enable ERT to draw on
Mr. Besier’s extensive experience and international
perspective in helping companies develop, implement and execute
global growth strategies to further penetrate health care and
clinical markets.

Mr. Besier brings to ERT more than 30 years of executive
experience in leading software technology companies. He has served
as President and CEO of SAP America, Inc. and is credited with
driving its growth in North and South America, Australia and New
Zealand from $50 million to $1 billion in revenues in less than
five years. In addition, as President and CEO of Firepond Inc., Mr.
Besier took the company public in one of the most successful IPOs
of 2000.

Mr. Besier also held the position of President and CEO of
Neoware, Inc., where he drove significant changes in the company’s
go-to-market and partner strategies. The improved corporate
structure led to significant growth and visibility for the
organization, resulting in its acquisition by HP in 2007 with a
total transaction value of more than $300 million. Most recently,
Mr. Besier served as CEO of Pramata, Inc., where he refined a
go-to-market strategy that is steering the company toward growth
with Fortune 500 customers. Today, he is the CEO of RES Software
and a member of the Board of Directors of ICG Commerce.

Joel Morganroth, Chairman and Chief Scientific Officer of ERT,
comments, “ERT strives to continually improve in all areas of
business and grow into adjacent and complementary markets, ensuring
our pledge to our customers of ‘getting it done right.’
With his wealth of experience and capabilities in developing and
implementing successful growth strategies, we are confident that
Klaus will greatly contribute to the strategic direction of the
business and help ERT achieve its many goals.” 

Klaus Besier adds, “As the industry leader in cardiac
safety, respiratory and multi-mode ePRO solutions for the clinical
trial market, ERT has provided unparalleled scientific and
regulatory leadership to the global health care industry. I am
delighted to be part of a strong management team consisting of
individuals who share a long industry track record. I look forward
to working with them to take ERT to an even higher level of
leadership and technological innovation.”

For further information on ERT and its technology and services,
please email info@ert.com,
call +1 215 972 0420 or visit www.ert.com.

For further press information, please contact Fiona Robinson,
The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel,
Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44
1477 539540, email ert@scottpr.com.

About ERT

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries.  The Company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG)
technology and services to evaluate cardiac safety in clinical
development. It is also a leading provider of centralized
respiratory technology and services to evaluate pulmonary function
efficacy and safety in clinical development.  Sponsors can
further use the Company’s solutions to streamline the
clinical trials process by automating the collection, analysis, and
distribution of ePRO clinical data using multi-mode technology in
all phases of clinical development as well as selected medical
devices for the clinical trials and healthcare industries.

Statements included in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a
number of risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied from such
statements. These risks and uncertainties include, without
limitation, the Company’s ability to obtain new contracts,
variability in size, scope, and duration of projects, integration
of acquisitions, competitive factors, technological development,
market demand, and other factors described in the Company’s
filings with the Securities and Exchange Commission.  The
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.

Media Contacts:

Fiona Robinson

The Scott Partnership

Tel: +44 1477 539539

ert@scottpr.com

John Blakeley

ERT

+1 215 972 0420

jblakeley@ert.com 

SOURCE